1,456 reports of this reaction
2.4% of all BELIMUMAB reports
#7 most reported adverse reaction
NAUSEA is the #7 most commonly reported adverse reaction for BELIMUMAB, manufactured by GlaxoSmithKline LLC. There are 1,456 FDA adverse event reports linking BELIMUMAB to NAUSEA. This represents approximately 2.4% of all 60,128 adverse event reports for this drug.
Patients taking BELIMUMAB who experience nausea should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
NAUSEA is a less commonly reported adverse event for BELIMUMAB, but still significant enough to appear in the safety profile.
In addition to nausea, the following adverse reactions have been reported for BELIMUMAB:
The following drugs have also been linked to nausea in FDA adverse event reports:
NAUSEA has been reported as an adverse event in 1,456 FDA reports for BELIMUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
NAUSEA accounts for approximately 2.4% of all adverse event reports for BELIMUMAB, making it a notable side effect.
If you experience nausea while taking BELIMUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.